Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2494378 | 0.79 | CYP2B6 (0.46) | CYP2B6ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL14354381 | 0.78 | CYP2B6 (0.39) | CYP2B6ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2488716 | 0.77 | CYP2B6 (0.42) | CYP2B6ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2128441 | 0.77 | CYP2B6 (0.45) | CYP2B6ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2127690 | 0.77 | CYP2B6 (0.45) | CYP2B6ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2491954 | 0.74 | CYP2B6 (0.53) | CYP2B6ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL6552278 | 0.73 | CYP2B6 (0.62) | CYP2B6MEN1KMT2AL3MBTL1CHRM3 | |
| SCHEMBL3836173 | 0.72 | CYP2B6 (0.40) | CYP2B6ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2494585 | 0.71 | CYP2B6 (0.50) | CYP2B6ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL874172 | 0.69 | CASR (0.53) | ALDH1A1GABRA1GABRB2CASRCHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957081-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2015-02-17 | — | — | US | claimed |
| US-20130005748-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2013-01-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005748-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | CYP2B6 4744/4885ALDH1A1 2982/4885GABRA1 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.